HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Protease Inhibitors (Protease Inhibitor)

Subscribe to New Research on Protease Inhibitors

Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).

Also Known As:

Protease Inhibitor; Antiproteases; Antagonists, Protease; Hydrolase Inhibitors, Peptide; Inhibitor, Protease; Inhibitors, Endopeptidase; Inhibitors, Peptidase; Inhibitors, Peptide Hydrolase; Inhibitors, Peptide Peptidohydrolase; Inhibitors, Protease; Peptidohydrolase Inhibitors, Peptide; Endopeptidase Inhibitors; Peptidase Inhibitors; Peptide Hydrolase Inhibitors; Peptide Peptidohydrolase Inhibitors; Protease Antagonists

Networked: 4307 relevant articles (270 outcomes, 416 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 56
  - Molecular Mechanisms of Pharmacological Action: 7
    - Enzyme Inhibitors: 685
      - Protease Inhibitors: 4307
        Angiotensin-Converting Enzyme Inhibitors: 8700
        HIV Protease Inhibitors: 251
        Serine Proteinase Inhibitors: 222
        Cysteine Proteinase Inhibitors: 116
        Dipeptidyl-Peptidase IV Inhibitors: 87

Experts

1.	Zeuzem, Stefan: 25 articles (06/2015 - 09/2007)
2.	Kobayashi, Hiroshi: 17 articles (01/2013 - 03/2002)
3.	Lawitz, Eric: 15 articles (01/2016 - 04/2012)
4.	Pol, Stanislas: 15 articles (10/2015 - 01/2006)
5.	Manfredi, Roberto: 14 articles (02/2014 - 01/2004)
6.	Sulkowski, Mark S: 13 articles (07/2014 - 01/2002)
7.	Suzuki, Mika: 13 articles (01/2005 - 03/2002)
8.	Marcellin, Patrick: 12 articles (05/2015 - 12/2010)
9.	Terao, Toshihiko: 12 articles (11/2004 - 03/2002)
10.	Kanayama, Naohiro: 12 articles (11/2004 - 03/2002)

Related Diseases

1.	Infection 10/11/1999 - "Human immunodeficiency virus 1 (HIV-1) protease inhibitors have dramatically reduced the morbidity and mortality due to HIV-1 infection. " 10/27/2006 - "The introduction of human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs) markedly improved the clinical outcome and control of HIV-1 infection. " 12/21/2013 - "The addition of HCV protease inhibitors to the SOC has significantly improved the efficacy of treatments for HCV infection. " 01/01/2015 - "The addition of protease inhibitors (PIs) changed the hepatitis C virus (HCV) treatment standards and improved sustained viral response (SVR) rates in patients with genotype 1 HCV infection. " 10/01/2012 - "Protease inhibitors have improved sustained virological response (SVR) rates for subjects with genotype 1 hepatitis C virus infection (HCV). "
2.	Pancreatitis 11/01/1999 - "These results indicate that intraperitoneal leakage of PLA2 plays an important role in bacterial translocation during acute pancreatitis and that administration of a protease inhibitor may be effective against the bacterial translocation." 01/01/2007 - "Additional research is needed to confirm the preventive efficacy of these antiproteases in patients at a high risk of developing post-ERCP pancreatitis." 10/01/2000 - "Therapeutic efficacy of continuous arterial infusion of an antibiotic and a protease inhibitor via the superior mesenteric artery for acute pancreatitis in an animal model." 04/01/2008 - "Protease inhibitors showed protective effects on animal models of acute pancreatitis when administered before induction of pancreatitis, and results when administered after induction are uncertain. " 01/01/2009 - "This study provides a clear rationale for further research to investigate the efficacy of enteral protease inhibitors in the treatment of acute pancreatitis."
3.	HIV Infections (HIV Infection) 08/01/2007 - "Protease inhibitors were a major therapeutic breakthrough in the mid-1990s for the treatment of HIV infection, which resulted in improved life expectancy for patients who had failed previous therapies. " 05/12/1999 - "Combination antiretroviral therapy including protease inhibitors (combo+PI) is effective in suppressing systemic viral load in HIV infection, but its impact on HIV-associated cognitive impairment is unclear. " 06/01/2010 - "[Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy]." 03/01/2003 - "Having changed the landscape in the treatment of HIV infection, the functional efficacy of current protease inhibitors (PIs) remains limited by their pharmacokinetic and pharmacodynamic profiles. " 02/01/1999 - "The advent of improved medical therapy with multidrug HIV medicines including protease inhibitors has prolonged life expectation of patients with HIV infection. "
4.	Acquired Immunodeficiency Syndrome (AIDS) 07/01/2004 - "Although new treatments have significantly improved the physical health of those living with HIV/AIDS, no evidence was found that these treatments significantly improved psychological health for women, regardless of history of protease inhibitor use." 02/01/2002 - "Protease inhibitor combination therapies have significantly improved the health of many people with HIV/AIDS. " 09/01/1997 - "The safety and efficacy of two successive sessions of WBHT (4 days apart) was evaluated in 30 patients with AIDS (not on protease inhibitors), randomized to: 1) untreated controls, 2) low temperature WBHT for 1 hour at 40 degrees C and repeated 96 hours later, and 3) high temperature WBHT for 1 hour at 42 degrees C and repeated 96 hours later. " 10/01/2008 - "Therefore, the incomplete suppression of HIV in treatment-experienced AIDS patients will continue to drive the search for more effective therapeutic agents that exhibit efficacy against the mutants raised by the earlier generation of protease inhibitors. " 09/01/1997 - "Double protease inhibitor combinations may be effective in some AIDS patients who do not respond to or who are intolerant of routines with a single protease inhibitor, according to an in vitro study at Harvard. "
5.	Hepatitis C 01/01/2015 - "The first generation protease inhibitors has been the mainstay of hepatitis C treatment for the last couple of years, showing marked improvement in sustained virological response, but also increased side effects. " 10/01/2014 - "With the introduction of the first-generation protease inhibitors the efficacy of hepatitis C treatment improved significantly. " 03/01/2013 - "An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver." 01/01/2013 - "A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients." 11/01/2015 - "Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake."

Related Drugs and Biologics

1.	Ribavirin (Virazole)
2.	telaprevir
3.	Interferons
4.	Ritonavir (Norvir)
5.	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamide
6.	Gabexate (Foy)
7.	Reverse Transcriptase Inhibitors
8.	Protease Inhibitors (Protease Inhibitor)
9.	Caerulein (Ceruletide)
10.	Indinavir (Crixivan)

Related Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART)
2.	Intra-Arterial Infusions
3.	Ligation
4.	Transplants (Transplant)
5.	Drug Therapy (Chemotherapy)